Cargando…
IgG(3) (+) B cells are associated with the development of multiple sclerosis
OBJECTIVES: Disease‐modifying therapies (DMTs) targeting B cells are amongst the most effective for preventing multiple sclerosis (MS) progression. IgG(3) antibodies and their uncharacterised B‐cell clones are predicted to play a pathogenic role in MS. Identifying subsets of IgG(3) (+) B cells invol...
Autores principales: | Marsh‐Wakefield, Felix, Ashhurst, Thomas, Trend, Stephanie, McGuire, Helen M, Juillard, Pierre, Zinger, Anna, Jones, Anderson P, Kermode, Allan G, Hawke, Simon, Grau, Georges E, Hart, Prue H, Byrne, Scott N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190396/ https://www.ncbi.nlm.nih.gov/pubmed/32355561 http://dx.doi.org/10.1002/cti2.1133 |
Ejemplares similares
-
Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA(+) Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM(+) Cell Signature
por: Leffler, Jonatan, et al.
Publicado: (2022) -
Peripheral B‐cell dysregulation is associated with relapse after long‐term quiescence in patients with multiple sclerosis
por: Marsh‐Wakefield, Felix, et al.
Publicado: (2022) -
Circulating CCR6
(+)
ILC proportions are lower in multiple sclerosis patients
por: Aglas‐Leitner, Florentina, et al.
Publicado: (2022) -
Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients
por: Nguyen, Kristy, et al.
Publicado: (2022) -
Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier
por: Lin, Linda Y., et al.
Publicado: (2023)